National Academy of Medicine

Aligning Cultural and Financial Incentives for Clinical Trials

By Arthur H. Rubenstein
May 04, 2012 | Commentary

One session of the November 2011 Institute of Medicine (IOM) workshop Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 focused on the need to develop new economic models for clinical trials and to change the environment in which they currently operate (IOM, 2012). The rationale for this approach is the general agreement that the present climate, in which clinical trials are carried out in the United States, is too expensive and organizationally complicated, resulting in fewer trials being planned, performed, and completed in this country. This fact has serious implications for the U.S. population. The presenters were asked to suggest new approaches that could reverse this situation.


Disclaimer: The views expressed in this paper are those of the authors and not necessarily of the authors’ organizations, the National Academy of Medicine (NAM), or the National Academies of Sciences, Engineering, and Medicine (the National Academies). The paper is intended to help inform and stimulate discussion. It is not a report of the NAM or the National Academies. Copyright by the National Academy of Sciences. All rights reserved.